Epoetin delta approved for use in NHS Wales
Epoetin delta and intravenous topotecan have been recommended for use
within NHS Wales, following Ministerial ratification of recommendations
made at the February meeting of the All Wales Medicines Strategy Group.
Epoetin delta (Dynepo) has been recommended for the treatment of anaemia
in patients with chronic renal failure. Intravenous topotecan (Hycamtin)
has been approved for two indications. It is recommended for patients
with relapsed small cell lung cancer for whom retreatment with the first-line
regimen is not considered appropriate. It has also been approved, in
combination with cisplatin, for cisplatin-naive patients with carcinoma
of the cervix recurrent after radiotherapy or with stage IVB carcinoma
of the cervix.
A positive recommendation by the AWMSG places an obligation on trusts
and local health boards in Wales to fund treatment, but AWMSG advice
is interim to any subsequent National Institute for Health and Clinical
Excellence guidance.
Tacrolimus (Advagraf) was not recommended for the indications the AWMSG
assessed: prophylaxis of transplant rejection in adult kidney or liver
allograft recipients and treatment of allograft rejection resistant to
treatment with other immunosuppressive medicines in adult patients.
|
The
Pharmaceutical Journal
Acrobat
Reader